Citable filing context
CL's research view summarizes recent SEC filing context, starting with earnings from Jul 31, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 31, 2026 | earnings | Colgate-Palmolive reported Q2 2026 net sales of $5.36 billion and GAAP EPS of $0.86. |
| May 13, 2026 | other | Colgate-Palmolive reported results of its May 8, 2026, annual meeting, including director elections and auditor ratification. |
| May 1, 2026 | earnings | Colgate-Palmolive reported Q1 2026 net sales of $5.32 billion and GAAP diluted EPS of $0.80. |
| Jul 31, 2026 | Guidance: net_sales_growth | 2.00 to 6.00 |
| Jul 31, 2026 | Guidance: organic_sales_growth | 1.00 to 4.00 |
| Oct 28, 2022 | Guidance: eps_growth | -8.00 to -7.00 |
| Jul 31, 2026 | mda_quarterly | Colgate-Palmolive’s capital allocation strategy remains focused on aggressive share repurchases, underpinned by the 2025 Program authorized by the Board on March 20, 2025. This $5 billion authorization replaced the company’s prior repurchase program, signaling a continued commitment to returning capital to shareholders. During the second quarter of 2026, the company executed significant buyback activity, repurchasing approximately 3.2 million shares at an average price of $87.40 per share. Monthly purchase volumes were relatively consistent, with 1.19 million shares acquired in April, 895,741 in May, and 1.13 million in June. As of June 30, 2026, the company maintained substantial liquidity for further repurchases, with approximately $3.53 billion remaining under the 2025 Program. Beyond the public program, the company continues to repurchase shares to satisfy obligations related to employee compensation and benefit plans, accounting for 27,946 shares surrendered during the quarter. These transactions are conducted at management’s discretion, contingent upon prevailing market conditions and internal blackout periods. This sustained repurchase activity reflects the company’s ongoing efforts to manage its equity base and optimize capital structure while navigating broader market volatility. |
| May 1, 2026 | mda_quarterly | The Board authorized a new $5 billion share repurchase program on March 20, 2025, replacing the company's previous authorization. Alongside this program, the company performs ongoing repurchases to satisfy compensation and benefit program requirements. During the first quarter of 2026, Colgate-Palmolive repurchased a total of 3,386,850 shares at an average price of $90.28 per share. Monthly volume fluctuated, with 3,038 shares purchased in January, 975,160 in February, and 2,408,652 in March. Of the total quarterly volume, 3,095,656 shares were executed under publicly announced programs, while 291,194 shares were acquired to satisfy employee elections within compensation and benefit plans. As of March 31, 2026, approximately $3.809 billion remains available for purchase under the company's publicly announced repurchase programs. |
Source: SEC EDGAR filing text and events; period Jul 31, 2026; filed Jul 31, 2026.
CL company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.